Mevlyq
Analogs of Mevlyq
Find cheaper analogs and generic equivalents for Mevlyq.
Active Ingredient: Eribulin mesylate
Product Overview
About Mevlyq
Mevlyq is a cancer medicine.
What it is used for
Not available in the source facts.
How it is used
Mevlyq treatment should be given under the supervision of a doctor experienced in the use of cancer medicines. Mevlyq is given as intravenous (into a vein) injections over 21‑day cycles. The dose to be given is calculated using the patient’s height and weight. The calculated dose is given into a vein over two to five minutes on days 1 and 8 of each cycle. Doctors should consider giving patients an antiemetic (a medicine that prevents nausea and vomiting) as Mevlyq may cause nausea or vomiting. Doses may be delayed or reduced if patients have very low levels of neutrophils (a type of white blood cell) and platelets (components that help the blood to clot) in their blood or if liver or kidney function is impaired.
How it works
The active substance in Mevlyq, eribulin, is similar to an anticancer substance called halichondrin B, which is found in the marine sponge Halichondria okadai. It attaches to a protein in cells called tubulin, which is important in the formation of the internal ‘skeleton’ that cells need to assemble when they divide. By attaching to tubulin in cancer cells, eribulin disrupts the formation of the skeleton, preventing the division and spread of the cancer cells.
Active substance: Eribulin
Visitor ratings
Help others by rating how useful this product page is.
No ratings yet — be the first.
